Avacta Group PLC Directorate Change (3020J)
March 29 2018 - 1:02AM
UK Regulatory
TIDMAVCT
RNS Number : 3020J
Avacta Group PLC
29 March 2018
29 March 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Directorate Change
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, announces that Dr Michael
Albin, one of the Group's Non-Executive Directors will be stepping
down from the Board with effect from 30 March 2018.
Dr Alastair Smith, Group Chief Executive Officer, commented:
"I would like to thank Michael for his contribution to the Group
over the last four years, his advice and support around the
development of our Affimer technology has been invaluable. I am
glad that Michael's association with Avacta will continue in an
advisory capacity."
- Ends -
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 844 414
Alastair Smith, Chief Executive 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0) 207 220
Geoff Nash / Giles Rolls 0500
- Nominated Adviser www.finncap.com
Tim Redfern / Alice Lane
/ Nikita Jain - Corporate
Broking
Tel: +44 (0) 203 705
WG Partners 9318
Nigel Birks / Nigel Barnes Tel: +44 (0) 203 705
David Wilson / Claes Spang 9217
www.wgpartners.co.uk
Zyme Communications (Trade Tel: +44 (0)7787 502
and Regional Media) 947
Katie Odgaard katie.odgaard@zymecommunications.com
Yellow Jersey PR (Financial Tel: +44 (0)7764 947137
Media and IR) avacta@yellowjerseypr.com
Sarah Hollins
To register for Avacta news alerts by email go to
www.avacta.com/investor-news-email-alerts
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFFEVTITFIT
(END) Dow Jones Newswires
March 29, 2018 02:02 ET (06:02 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024